SCHEMBL1663873

SCHEMBL1663873

O=C(CCc1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 7/20 0.62
▸ CES1 P23141 7/20 0.62
▸ KEAP1 Q14145 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.55
▸ FFAR1 O14842 1/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ CASP3 P42574 1/20 0.55
▸ SENP8 Q96LD8 1/20 0.55
▸ SENP7 Q9BQF6 1/20 0.55
▸ SENP6 Q9GZR1 1/20 0.55
▸ PLAAT5 Q96KN8 1/20 0.55
▸ PLAAT4 Q9UL19 1/20 0.55
▸ HDAC2 Q92769 3/20 0.52
▸ HDAC8 Q9BY41 3/20 0.52
▸ HDAC6 Q9UBN7 3/20 0.52
▸ HDAC1 Q13547 3/20 0.50
▸ HDAC3 O15379 2/20 0.50
▸ HDAC4 P56524 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9372200 0.88 KEAP1 (0.55) CES2CES1KEAP1ALDH1A1FFAR1
SCHEMBL8947362 0.88 NPC1 (0.67) CES2CES1KEAP1TDP1NPC1
SCHEMBL29242652 0.86 CES1 (0.66) CES2CES1TDP1NPC1RAB9A
SCHEMBL14141728 0.84 CES2 (0.75) CES2CES1ALDH1A1TDP1MAPK1
SCHEMBL4279627 0.84 KEAP1 (0.73) CES2CES1KEAP1ALDH1A1FFAR1
SCHEMBL10343974 0.83 RAB9A (0.62) CES2CES1KEAP1ALDH1A1NPC1
SCHEMBL29078123 0.80 KEAP1 (0.67) CES2CES1KEAP1ALDH1A1FFAR1
SCHEMBL258545 0.80 KEAP1 (0.67) CES2CES1KEAP1ALDH1A1FFAR1
SCHEMBL11479618 0.80 FFAR1 (0.61) CES2CES1KEAP1ALDH1A1FFAR1
SCHEMBL340540 0.78 CES2 (0.70) CES2CES1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-55038359-A — — None — — JP disclosed
CN-106822349-B Preparation method of Xinxin Shu capsule 陕西东科制药有限责任公司 2020-02-14 — — CN disclosed
CN-105601483-A Synthetic method of medical intermediate 1,4-diphenyl butanedione UNIV WENZHOU MEDICAL 2016-05-25 — — CN disclosed
CN-105601483-A Synthetic method of medical intermediate 1,4-diphenyl butanedione UNIV WENZHOU MEDICAL 2016-05-25 — — CN disclosed
EP-0885192-B8 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2012-05-16 — — EP disclosed
EP-2311806-A2 Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists The United States of America, Represented by the Secretary, Department of Health and Human Services (US) 2011-04-20 — — EP disclosed
US-20100204245-A1 Amino-pyridines As Inhibitors Of Beta-secretase WYETH LLC (US) 2010-08-12 — — US disclosed
US-7732457-B2 Amino-pyridines as inhibitors of β-secretase WYETH LLC (US) 2010-06-08 — — US disclosed
US-20060173049-A1 enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease WYETH (US) 2006-08-03 — — US disclosed
US-6066642-A FOR SELECTIVELY BLOCKING THE A3 ADENOSINE RECEPTOR OF A MAMMAL THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-05-23 — — US disclosed
EP-0885192-A1 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 1998-12-23 — — EP disclosed
WO-1997027177-A2 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN-4-ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-07-31 — — WO disclosed
JP-S5538359-A PREPARATION OF 2-(3-BENZOYLPHENYL)-PROPIONIC ACID HAMARI YAKUHIN KOGYO KK 1980-03-17 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204245-A1 Amino-pyridines As Inhibitors Of Beta-secretase BACE1, BACE2, APP CES2 2332/4885CES1 1330/4885KEAP1 607/4885
US-20060173049-A1 enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease BACE1, BACE2, PSEN1 CES2 1195/4885CES1 526/4885KEAP1 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback